NCT06917209 Evaluation of the Efficacy of Dissociation-Focused Cognitive Behavior Therapy
| NCT ID | NCT06917209 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Tours |
| Condition | Dissociative Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 140 participants |
| Start Date | 2025-05-16 |
| Primary Completion | 2026-08-22 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 140 participants in total. It began in 2025-05-16 with a primary completion date of 2026-08-22.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Dissociative symptoms and disorders are particularly prevalent in the general population and among people suffering from psychiatric disorders. To date, no treatment has proven effective for this type of problem. Exploratory studies (without control group) have been carried out. Among these studies, dissociation-focused cognitive behavioral therapy (DF-CBT) seems promising. DF-CBT is based on a solid empirical model that has received numerous scientific evidence.
Eligibility Criteria
Inclusion Criteria: * ≥ 18 years * Membership of a social security scheme * Participant's express consent * Have at least one diagnosis of dissociative disorder among the following: depersonalization/derealization disorder, dissociative identity disorder, unspecified dissociative disorder. * Be able to carry out psychotherapy sessions. * If taking psychiatric medication, treatment must have been stable for at least 30 days. Exclusion Criteria: * Present one of the following current diagnoses: substance use disorder (excluding tobacco), neurodevelopmental disorder, anorexia nervosa, severe depressive disorder, schizophrenia spectrum disorder, bipolar disorder, personality disorder other than borderline personality disorder. * Present cognitive deficits. * Be engaged in psychotherapeutic work. * Be undergoing benzodiazepine treatment.
Contact & Investigator
Alexis VANCAPPEL, PhD
STUDY CHAIR
Clinique Psychiatrique Universitaire / CHRU de Tours
Frequently Asked Questions
Who can join the NCT06917209 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Dissociative Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06917209 currently recruiting?
Yes, NCT06917209 is actively recruiting participants. Contact the research team at alexis.vancappel@univ-tours.fr for enrollment information.
Where is the NCT06917209 trial being conducted?
This trial is being conducted at Angers, France, Lille, France, Montpellier, France, Nantes, France and 4 additional locations.
Who is sponsoring the NCT06917209 clinical trial?
NCT06917209 is sponsored by University Hospital, Tours. The principal investigator is Alexis VANCAPPEL, PhD at Clinique Psychiatrique Universitaire / CHRU de Tours. The trial plans to enroll 140 participants.